Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Depreciation & Amortization (CF) (2016 - 2025)

Corcept Therapeutics' Depreciation & Amortization (CF) history spans 10 years, with the latest figure at $289000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 2.85% year-over-year to $289000.0; the TTM value through Dec 2025 reached $1.1 million, up 44.53%, while the annual FY2025 figure was $1.1 million, 44.53% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $289000.0 at Corcept Therapeutics, roughly flat from $289000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.2 million in Q2 2021 and bottomed at -$1.7 million in Q3 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $283000.0 (2024), against an average of $265850.0.
  • The largest YoY upside for Depreciation & Amortization (CF) was 1687.9% in 2021 against a maximum downside of 2085.88% in 2021.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $289000.0 in 2021, then skyrocketed by 128.37% to $660000.0 in 2022, then plummeted by 67.58% to $214000.0 in 2023, then soared by 31.31% to $281000.0 in 2024, then rose by 2.85% to $289000.0 in 2025.
  • Per Business Quant, the three most recent readings for CORT's Depreciation & Amortization (CF) are $289000.0 (Q4 2025), $289000.0 (Q3 2025), and $286000.0 (Q2 2025).